BioSpace News Archive

PLx Pharma Inc., a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg liquid-filled aspirin capsules, announced that VAZALORE is now on shelves at major retailers and e-commerce sites nationwide.

The Delta Dental Institute announced three new research awards to leading health research institutions.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced preliminary results of a new preclinical study showing strong inhibition by opaganib [1] of Delta variant replication while maintaining cell viability at relevant concentrations.

Nevro Corp. announced that D. Keith Grossman, Nevro’s Chairman, CEO and President, will present at the Baird 2021 Global Healthcare Conference on Wednesday, September 15, 2021 at 10:50 am Eastern Time / 7:50 am Pacific Time.

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that management will present and host one-on-one meetings at the following investor conferences during the month of September 2021.

Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced that the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham has joined Caris’ Precision Oncology Alliance™.

Neurogastrx, Inc., a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal disorders, announced the successful completion of a $60 million Series B crossover round led by Vivo Capital.

TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, announced the appointment of Priti Hegde, Ph.D., to its Board of Directors.

Pfizer Inc. and BioNTech SE announced the signing of a letter of intent with Eurofarma Laboratórios SA, a Brazilian biopharmaceutical company, to manufacture COMIRNATY® for distribution within Latin America.

NRx Pharmaceuticals announced today it has signed an agreement with Cardinal Health to provide third party logistics and distribution of ZYESAMI™ upon the potential Emergency Use Authorization (EUA) approval by the US Food and Drug Administration (FDA).